Bristol Myers Squibb (CELG-RI) Non-Current Assets (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Non-Current Assets of $59.1 billion for Q2 2026, down 3.9% year-over-year from $61.5 billion in Q2 2025, and little changed quarter-over-quarter from $59.3 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Non-Current Assets (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Non-Current Assets for 18 consecutive years, with $59.1 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets fell 3.9% year-over-year to $59.1 billion; the TTM figure through Jun 2026 stood at $240.2 billion (down 4.49% YoY), while the FY2025 annual figure was $60.6 billion, down 3.46% from the prior year.
- Non-Current Assets held at $59.1 billion in Q2 2026 per CELG-RI's latest filing, from $59.3 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $72.9 billion in Q1 2022 and bottomed at $59.1 billion in Q2 2026.
- Historically, Non-Current Assets has averaged $65.2 billion across 5 years, with a median of $64.5 billion in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets slipped 14.55% — and 2024, when it increased 4.71%.
- Bristol Myers Squibb's Non-Current Assets stood at $69.5 billion in 2022, then fell by 8.85% to $63.4 billion in 2023, then fell by 0.89% to $62.8 billion in 2024, then fell by 3.46% to $60.6 billion in 2025, then slipped by 2.63% to $59.1 billion in 2026.
- Business Quant data shows CELG-RI's Non-Current Assets at $59.1 billion in Q2 2026, $59.3 billion in Q1 2026, and $60.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.04 Bn | 633.28 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 470.61 Bn | 464.04 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 379.00 Bn | 371.86 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 303.30 Bn | 295.61 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 258.47 Bn | 253.57 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 237.78 Bn | 223.79 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 183.75 Bn | 180.57 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 160.91 Bn | 149.21 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 106.07 Bn | 101.90 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 59.06 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.06 Bn |
| Mar 31, 2026 | 59.27 Bn |
| Dec 31, 2025 | 60.65 Bn |
| Sep 30, 2025 | 61.26 Bn |
| Jun 30, 2025 | 61.45 Bn |
| Mar 31, 2025 | 61.64 Bn |
| Dec 31, 2024 | 62.82 Bn |
| Sep 30, 2024 | 65.60 Bn |
| Jun 30, 2024 | 67.76 Bn |
| Mar 31, 2024 | 70.36 Bn |
| Dec 31, 2023 | 63.39 Bn |
| Sep 30, 2023 | 63.63 Bn |
| Jun 30, 2023 | 65.42 Bn |
| Mar 31, 2023 | 67.20 Bn |
| Dec 31, 2022 | 69.55 Bn |
| Sep 30, 2022 | 71.40 Bn |
| Jun 30, 2022 | 70.17 Bn |
| Mar 31, 2022 | 72.91 Bn |
| Dec 31, 2021 | 76.05 Bn |
| Sep 30, 2021 | 79.45 Bn |